Showing results (411-420 of 440) with videos related to

Sort By:
Pageof 44
Medical Care|December 22, 2025
Magnet4Europe Intervention to Improve Clinician and Patient Well-Being: A Quasi-Experimental Study of 56 Hospitals in 6 European CountriesLinda H Aiken, Walter Sermeus, Karen B Lasater, et al.
Antibiotics (Basel, Switzerland)|June 26, 2026
Comparison of Environmental Microbiomes, Resistomes and Plasmidomes from a Human Tertiary Hospital and Companion Animal Veterinary Hospital in London, UKLinzy Elton, Stuart Lutimba, Alonso Dupuy Mateos, et al.
The Journal of Infectious Diseases|April 6, 2012
Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needsAlimuddin Zumla, Ibrahim Abubakar, Mario Raviglione, et al.
BMJ Open|July 28, 2022
A workplace organisational intervention to improve hospital nurses' and physicians' mental health: study protocol for the Magnet4Europe wait list cluster randomised controlled trialWalter Sermeus, Linda H Aiken, Jane Ball, et al.
The Lancet. Respiratory Medicine|January 28, 2014
Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational studyJosephine M Bryant, Simon R Harris, Julian Parkhill, et al.
The Pediatric Infectious Disease Journal|February 28, 2023
Rapid and Accurate Diagnosis of Pediatric Tuberculosis Disease: A Diagnostic Accuracy Study for Pediatric TuberculosisLaura Olbrich, Marriott Nliwasa, Issa Sabi, et al.
Mucosal Immunology|November 25, 2023
Salivary IgA and vimentin differentiate in vitro SARS-CoV-2 infection: A study of 290 convalescent COVID-19 patientsSamuel Ellis, Rosie Way, Miranda Nel, et al.
Journal of Clinical Microbiology|May 15, 2015
Rapid Whole-Genome Sequencing of Mycobacterium tuberculosis Isolates Directly from Clinical SamplesAmanda C Brown, Josephine M Bryant, Katja Einer-Jensen, et al.
Trials|June 6, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosisA Dierig, M Hoelscher, S Schultz, et al.
The Lancet. Microbe|January 10, 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trialNorbert Heinrich, Veronique de Jager, Julia Dreisbach, et al.
Pageof 44